Key statistics
On Friday, Allurion Technologies Inc (ALUR:NYQ) closed at 1.10, 15.79% above the 52 week low of 0.95 set on Feb 04, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.06 |
|---|---|
| High | 1.14 |
| Low | 1.04 |
| Bid | 1.00 |
| Offer | 1.16 |
| Previous close | 1.07 |
| Average volume | 114.80k |
|---|---|
| Shares outstanding | 12.28m |
| Free float | 11.50m |
| P/E (TTM) | -- |
| Market cap | 13.14m USD |
| EPS (TTM) | -9.20 USD |
Data delayed at least 15 minutes, as of Feb 06 2026 21:00 GMT.
More ▼
- Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices
- Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results
- Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
- New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone
- Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
- Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update
- Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing
More ▼
